Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.
Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer